[K-Bio Big Data Awards] Free Provision If Plasma Therapy Development Succeeds

Asia Economy Grand Prize - GC Green Cross

[Asia Economy Reporter Choi Dae-yeol] Keywords frequently associated with GC Green Cross include treatment, plasma, vaccine, and development. This is because the company is developing a plasma treatment expected to be the first COVID-19 treatment to be released domestically.

This treatment is made by collecting plasma from the blood of recovered patients and extracting antibodies with immunogenicity. It is considered a treatment that can be developed relatively quickly when a new infectious disease spreads, and is currently undergoing Phase 2 clinical trials. The company is highly regarded not only domestically but also globally for its blood products, with more than one-third of its sales coming from blood-derived products.

Heo Eun-cheol, CEO of GC Green Cross

As COVID-19 has entered a prolonged phase, interest in treatments and vaccines has increased among the general public, drawing attention to the development process. Keywords such as clinical, clinical trial, patient, and antibody ranking high are interpreted as reflecting this background. The company also attracted attention by announcing its intention to provide the treatment free of charge if development is successful.

Vaccines were also identified as one of the keywords symbolizing the company. Vaccine development is generally difficult and securing profitability is challenging, so pharmaceutical and bio companies are often reluctant to enter this field. GC Green Cross focuses on influenza and varicella vaccines and is also considering developing a universal vaccine related to COVID-19.

This content was produced with the assistance of AI translation services.